<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03063931</url>
  </required_header>
  <id_info>
    <org_study_id>CHU-306</org_study_id>
    <secondary_id>2016-A01749-42</secondary_id>
    <nct_id>NCT03063931</nct_id>
  </id_info>
  <brief_title>Pain and Magnesium</brief_title>
  <official_title>Effect of the Oral Route of Magnesium on Pre and Post-mastectomy on the Post-surgery Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Clermont-Ferrand</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Clermont-Ferrand</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In breast cancer patients undergoing a mastectomy, the aim of this study is to evaluate if
      the magnesium administered for 6 weeks starting two weeks before the surgery induces a
      decrease of pain intensity one month post-mastectomy compared to the placebo group.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, placebo-controlled double-blind clinical trial conducted in the
      Oncology Hospital, Clermont-Ferrand, France, in 100 patients suffering from breast cancer and
      undergoing a total mastectomy.

      This clinical trial compares magnesium and placebo for the prevention of neuropathic pain
      induced by mastectomy assessed with a (0-10) numerical pain rating scale. Cognition, anxiety,
      depression, sleep and quality of life are also assessed.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 2017</start_date>
  <completion_date type="Anticipated">April 2019</completion_date>
  <primary_completion_date type="Anticipated">March 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measure of average pain intensity by a numerical rating scale</measure>
    <time_frame>5 days before the visit at 1 month post-mastectomy</time_frame>
    <description>Measure of average pain intensity by a numerical rating scale assessed 5 days before the visit at 1 month post-mastectomy in magnesium and placebo groups.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain assessment by the Neuropathic pain questionnaire</measure>
    <time_frame>at month 1 and Month 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of analgesic consumption</measure>
    <time_frame>at 3 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive assessment by Trail Making Test A and B</measure>
    <time_frame>at month 1 and month 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life assessment by EORTC QLQ-C30</measure>
    <time_frame>at month 1 and month 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life assessment by Pittsburg Sleep Quality Index (PSQI)</measure>
    <time_frame>at month 1 and month 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anxiety and Depression assessment by DASS scale</measure>
    <time_frame>at month 1 and month 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma and erythrocyte assays of magnesium</measure>
    <time_frame>at inclusion visit, month 1 and month 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Creatinine dosage</measure>
    <time_frame>at inclusion visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine assays of magnesium</measure>
    <time_frame>at month 1 and month 3</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Neuropathic Pain Induced by Mastectomy</condition>
  <arm_group>
    <arm_group_label>magnesium</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Magnesium: Magnésium UPSA Action Continue®</intervention_name>
    <description>This clinical trial compares magnesium and placebo for the prevention of neuropathic pain induced by mastectomy assessed with a (0-10) numerical pain rating scale</description>
    <arm_group_label>magnesium</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo: Lactose</intervention_name>
    <description>This clinical trial compares magnesium and placebo for the prevention of neuropathic pain induced by mastectomy assessed with a (0-10) numerical pain rating scale</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  - Age ≥ 18 years,

          -  Patient with breast cancer who has a scheduled total mastectomy with or without
             treatment two weeks after inclusion with or without preoperative chemotherapy,

          -  Patient free from any new treatment or diet at the time of the inclusion,

          -  Cooperation and understanding sufficient to comply with the requirements of the study,

          -  Patients affiliated to the French Social Security,

          -  Patients with free and informed consent has been obtained

        Exclusion Criteria:

          -  Hypersensitivity to the active substance or to any of the excipients

          -  Patient with magnesemia &gt;1,05 mmol/l

          -  Patient with severe renal insufficiency with creatinine clearance &lt;30 ml min,

          -  Patient with an addiction to alcohol, as determined by the investigator,

          -  Diabetes (type I and II),

          -  Medical and surgical history incompatible with the study,

          -  Patient receiving treatment with Quinidine, L-Dopa,

          -  Childbearing age, no use of effective contraceptive method, pregnancy or lactation

          -  Patient exclusion period, or the total allowable compensation exceeded

          -  Patients undergoing a measure of legal protection (guardianship, supervision ...)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gisèle PICKERING</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Clermont-Ferrand</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Patrick LACARIN</last_name>
    <phone>04 73 75 11 95</phone>
    <email>placarin@chu-clermontferrand.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Clermont-Ferrand</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Patrick LACARIN</last_name>
      <phone>04 73 75 11 95</phone>
      <email>placarin@chu-clermontferrand.fr</email>
    </contact>
    <investigator>
      <last_name>Dominique JOLY</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christine VILLATTE</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christophe POMEL</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pierre GIMBERGUES</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xavier DURANDO</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Claude DUBRAY</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 21, 2017</study_first_submitted>
  <study_first_submitted_qc>February 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 24, 2017</study_first_posted>
  <last_update_submitted>February 24, 2017</last_update_submitted>
  <last_update_submitted_qc>February 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast cancer</keyword>
  <keyword>Mastectomy</keyword>
  <keyword>Pain</keyword>
  <keyword>Anxiety and Depression</keyword>
  <keyword>Cognition</keyword>
  <keyword>Quality of life</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuralgia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

